Rilzabrutinib has demonstrated sustained platelet responses and improved symptoms in patients with immune thrombocytopenia (ITP) according to long-term extension data from the LUNA 3 trial. Presented...
Researchers at The University of Texas MD Anderson Cancer Center have developed a novel antibody therapy, designated 77A, which has demonstrated potential in enhancing immune responses...
